Evidence map›Paper›PMID 36407458›Full record

ReviewFrontiers in cardiovascular medicine2022

Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices.

Ioannis Dimarakis, Paul Callan, Maziar Khorsandi, Jay D Pal, Claudio A Bravo, Claudius Mahr, Jeffrey E Keenan

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Recent Developments in Ventricular Assist Device Therapy.Reviews in cardiovascular medicine · 2025
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ioannis DimarakisDivision of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States.
Paul CallanDepartment of Cardiothoracic Transplantation, Manchester University Hospital NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom.
Maziar KhorsandiDivision of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States.
Jay D PalDivision of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States.
Claudio A BravoDivision of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States.
Claudius MahrDivision of Cardiology, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States.
Jeffrey E KeenanDivision of Cardiothoracic Surgery, Department of Surgery, University of Washington Medical Center, Seattle, WA, United States.
University of Washington Medical Center · USWythenshawe Hospital · GB

Funding

Training In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1M
UCSD PRIDE Faculty Development Program in Cardiovascular SciencesR25HL145817 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Robert Scott Ross, Joann Trejo · 2019 to 2026
$3.3M
NHLBI NIH HHS R25 HL145817NHLBI NIH HHS T32 HL007444
6 · The paper itself

Abstract

Over the last two decades, implantable continuous flow left ventricular assist devices (LVAD) have proven to be invaluable tools for the management of selected advanced heart failure patients, improving patient longevity and quality of life. The presence of concomitant valvular pathology, including that involving the tricuspid, mitral, and aortic valve, has important implications relating to the decision to move forward with LVAD implantation. Furthermore, the presence of concomitant valvular pathology often influences the surgical strategy for LVAD implantation. Concomitant valve repair or replacement is not uncommonly required in such circumstances, which increases surgical complexity and has demonstrated prognostic implications both short and longer term following LVAD implantation. Beyond the index operation, it is also well established that certain valvular pathologies may develop or worsen over time following LVAD support. The presence of pre-existing valvular pathology or that which develops following LVAD implant is of particular importance to the destination therapy LVAD patient population. As these patients are not expected to have the opportunity for heart transplantation in the future, optimization of LVAD support including ameliorating valvular disease is critical for the maximization of patient longevity and quality of life. As collective experience has grown over time, the ability of clinicians to effectively address concomitant valvular pathology in LVAD patients has improved in the pre-implant, implant, and post-implant phase, through both medical management and procedural optimization. Nevertheless, there remains uncertainty over many facets of concomitant valvular pathology in advanced heart failure patients, and the understanding of how to best approach these conditions in the LVAD patient population continues to evolve. Herein, we present a comprehensive review of the current state of the field relating to the pathophysiology and management of valvular disease in destination LVAD patients.

Indexed as

aortic insufficiencyheart failureleft ventricular assist deviceLVADmitral regurgitationtricuspid regurgitation

Identifiers

PMID36407458
PMCPMC9669306
OpenAlexW4308416663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.